Roche Diagnostics tests for suspected pre-eclampsia and heart attack have been recognized as ‘transformative’ and have been selected among only seven Rapid Uptake Products for the NHS.

The Basel-based pharmaceuticals company, Roche, has formed an alliance with the US Millennium group to develop diagnostic products for rheumatoid arthritis. Under the three-year deal, Millennium ...

Roche has a plan to build out its point-of-care diagnostic catalog, with the goal of delivering more tests to homes, pharmacies, doctor’s offices and elsewhere. The company aims to acquire a ...

According to Roche, the diagnostic’s expansion into the ultralow category may allow between 20% to 25% of patients whose breast tumors were previously labeled as HR-positive and HER2-negative to ...

Roche announced that customers in Canada may now order its portfolio of Kapa Biosystems next-generation sequencing (NGS) products directly from Roche ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered HER2-ultralow.1 These patients may now ...

Under the terms of the agreement, Roche will have non-exclusive access to SpeeDx existing tests and technology - to enable global access and expansion of diagnostic products for the management of ...

Roche hopes that, through our joint efforts, we will be able to provide companion diagnostic tests which lead to better solutions for patients worldwide.” said Paul Brown, Head of Roche ...

BASEL, Switzerland — Roche announced this week the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA.